Business
Haemonetics Corporation Announces Third Quarter Fiscal 2026 Financial Results Available on Investor Relations Website
Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2026, which ended December 27, 2025, are available on the Company's Investor Relations website at www.haemonetics.com.
About this update from Haemonetics Corporation
Financial release and supplemental presentation accessible online BOSTON , Feb. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2026, which ended December 27, 2025, are available on the Company's Investor Relations website at www.haemonetics.com . The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 5, 2026. Conference Call and Webcast Information: A replay of the conference call and webcast will be available beginning at 11:00 a.m. ET on February 5, 2026 and will remain accessible for one year via the webcast link above. Earnings Materials: Haemonetics has also posted the following materials on its Investor Relations website, which will be referenced during the conference call and webcast: ABOUT HAEMONETICS Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/haemonetics-corporation-announces-third-quarter-fiscal-2026-financial-results-available-on-investor-relations-website-302679292.html
View stock analysis, news, and events for Haemonetics Corporation